| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Daptomycin (also known as LY146032; LY-146032; trade name: Cubicin; Cidecin), a natural product isolated from the soil saprotroph Streptomyces roseosporus, is a novel lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms. It is a drug that has been approved for the treatment of infections brought on by Gram-positive bacteria that are systemic and potentially fatal. A naturally occurring substance called daptomycin is present in the soil saprotroph Streptomyces roseosporus. It can be used to treat infections brought on by multiple drug-resistant bacteria due to its unique mechanism of action. Cubist Pharmaceuticals markets it in the US under the trade name Cubicin. Daptomycin is a bactericidal antibiotic that acts both in vitro and in vivo against a wide range of Gram-positive bacteria. Daptomycin inhibits many antibiotic-resistant strains, including vancomycin-intermediate S. aureus (VISA), meticillin-resistant S. aureus (MRSA), and vancomycin-resistant S. aureus (VRSA). It is a cyclic lipopeptide.
| Targets |
Lipopeptide
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C72H101N17O26
|
|
|---|---|---|
| Molecular Weight |
1620.67
|
|
| Exact Mass |
1619.71
|
|
| Elemental Analysis |
C, 53.36; H, 6.28; N, 14.69; O, 25.67
|
|
| CAS # |
103060-53-3
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
|
|
| InChi Key |
OAKLVKFURWEDJ-RWDRXURGSA-N
|
|
| InChi Code |
InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
|
|
| Chemical Name |
(3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
|
|
| Synonyms |
LY146032; LY 146032; Daptomycin; Cidecin; LY-146032; LY146032; trade name: Cubicin
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (1.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (1.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (1.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (61.70 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6170 mL | 3.0851 mL | 6.1703 mL | |
| 5 mM | 0.1234 mL | 0.6170 mL | 1.2341 mL | |
| 10 mM | 0.0617 mL | 0.3085 mL | 0.6170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04775953 | Active Recruiting |
Drug: Daptomycin Drug: Nafcillin |
Staphylococcal Bacteraemia | National Institute of Allergy and Infectious Diseases (NIAID) |
April 22, 2021 | Phase 2 |
| NCT04983901 | Active Recruiting |
Drug: Daptomycin Drug: Linezolid |
Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm |
M.D. Anderson Cancer Center | September 14, 2021 | Phase 2 |
| NCT04141787 | Recruiting | Drug: Usual Antibiotics Drug: Ceftriaxone |
Osteomyelitis CNS Infection |
Vancouver Island Health Authority | July 11, 2019 | Phase 4 |
| NCT05225558 | Recruiting | Drug: Delpazolid Drug: Vancomycin |
MRSA Bacteremia | LegoChem Biosciences, Inc | April 26, 2022 | Phase 2 |
| NCT05174546 | Recruiting | Diagnostic Test: T2 magnetic resonance |
Febrile Neutropenia | The University of Queensland | January 10, 2023 | N/A |
|
|---|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
